ANABV
AnaptysBio, Inc. Common Stock When Issued • NASDAQ
$43.80 ▲ 1.86% (+0.80)
ANABV
AnaptysBio, Inc. Common Stock When IssuedNASDAQ • $43.80 ▲ 1.86% (+0.80)
Market Cap $1.26 B
52w High $49.76
52w Low $41.99
P/E 0
Volume 2.21K
Outstanding Shares 28.75M
Market Cap $1.26 B
52w High $49.76
52w Low $41.99
P/E 0
Volume 2.21K
Outstanding Shares 28.75M
About AnaptysBio, Inc. Common Stock When Issued
http://www.anaptysbio.comAnaptysBio, Inc. is a clinical stage biotechnology company. engages in the development of antibody product candidates. Its products pipeline include ANB030, ANB030, and Imsidolimab. It also offers SHM platform that replicate the natural process of somatic hypermutation embedded within the human immune system to rapidly develop a diverse range of therapeutic-grade antibodies in vitro.
CEO
Daniel R. Faga
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Biotechnology
Sector Healthcare
Went public April 6, 2026
Method of going public IPO
Full time employees 0
MAY
7 THU
Upcoming Earnings
Date May 7, 2026
Day Thursday
Revenue Est. $23.66M
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0